Resistance Oncology ApS: Financial statements 2023
CVR: 36945125
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Resistance Oncology ApS (CVR 36945125) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -21,005 and a net result of DKK -22,028 compared with DKK -10,252 the year before. Equity in the 2023 report amounted to DKK -63,459. The company had 1 employee in the financial year.
- Gross Profit
- DKK -21,005
- Profit/Loss
- DKK -22,028
- Equity
- DKK -63,459
- Total Assets
- DKK 49,163
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -21K | -22K | -63K | 1 |
| 2022 | - | -12K | -10K | -41K | - |
| 2021 | - | -10K | -9K | -31K | - |
| 2020 | - | -10K | -8K | -23K | - |
| 2019 | - | 14K | 10K | -15K | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
On August 25, 2023, the company changed its name from Cortris Nordic ApS to 3B-Oncology ApS.
Resistance Oncology ApS has published its annual report for 2022. Gross profit came to DKK -11,970, and the net result was DKK -10,252.
About Resistance Oncology ApS
Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Kasper Pasternak Jørgensen and Nils Aage Brünner. The company is owned by TIMPCO-RO ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity in the 2025 report amounted to DKK 325,631.